Cagrilintide
Also known as AM833, NN9838
Long-acting amylin analog for obesity treatment operating through distinct pathways compared to GLP-1 agonists. Phase 3: 11.8% weight loss (monotherapy); 20.4% (CagriSema combination).
Regulatory Pathway
Dosing Protocol
Typical Dose
2.4 mg weekly
Frequency
Once weekly
Duration
Long-term / chronic use expected
Timing & Administration
Administer via Subcutaneous injection. Frequency: Once weekly.
Popular Uses
Mechanism of Action
Mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. Activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling.
Research Summary
Evidence level: clinical trials. Clinical status: Phase 3 Trials - Not yet FDA approved.
Side Effects & Safety
Important Warnings
- GI events affected 79.6% in combination trials
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile